Identification of a Role for the Tyrosine Kinase JAK2 in Both Skeletal Muscle Mitogenesis and Myogenesis by Miller, Symantha A. & Reecy, James M.
Animal Industry Report Animal Industry Report 
AS 650 ASL R1866 
2004 
Identification of a Role for the Tyrosine Kinase JAK2 in Both 
Skeletal Muscle Mitogenesis and Myogenesis 
Symantha A. Miller 
Iowa State University 
James M. Reecy 
Iowa State University 
Follow this and additional works at: https://lib.dr.iastate.edu/ans_air 
 Part of the Agriculture Commons, and the Animal Sciences Commons 
Recommended Citation 
Miller, Symantha A. and Reecy, James M. (2004) "Identification of a Role for the Tyrosine Kinase JAK2 in 
Both Skeletal Muscle Mitogenesis and Myogenesis," Animal Industry Report: AS 650, ASL R1866. 
DOI: https://doi.org/10.31274/ans_air-180814-710 
Available at: https://lib.dr.iastate.edu/ans_air/vol650/iss1/25 
This Animal Products is brought to you for free and open access by the Animal Science Research Reports at Iowa 
State University Digital Repository. It has been accepted for inclusion in Animal Industry Report by an authorized 
editor of Iowa State University Digital Repository. For more information, please contact digirep@iastate.edu. 
Iowa State University Animal Industry Report 2004 Animal Products
Identification of a Role for the Tyrosine Kinase JAK2 in Both
Skeletal Muscle Mitogenesis and Myogenesis
A.S. Leaflet R1866
Symantha A. Miller, Graduate Research Assistant, and
James M. Reecy, Assistant Professor of Animal Science.
Summary and Implications
This study was conducted to investigate what roles
JAK2 might play in skeletal myoblast proliferation and
terminal differentiation.  These results represent the first
characterization of the requirement of JAK2 in skeletal
muscle proliferation, and suggest a novel role, potentially
independent of kinase activity, for JAK2 in skeletal muscle
myogenesis.
Introduction
Janus kinase 2 (JAK2) promotes proliferation in a wide
variety of cell types and a number of cancers.  Adult skeletal
muscle contains a unique population of muscle stem cells
called satellite cells that are found between the basal lamina
and cell membrane of adult skeletal muscle.  During
embryonic development and postnatal hypertrophy, skeletal
myoblasts and satellite cells proliferate and ultimately
differentiate into multinucleated cells.  These cells exist in a
quiescent state unless activated to proliferate and fuse to
existing muscle fibers.  This study was conducted to
investigate what roles JAK2 might play in skeletal myoblast
proliferation and terminal differentiation.  We used AG490,
a JAK2-specific inhibitor, and dominant negative JAK2
(DN-JAK2) to demonstrate that catalytically active JAK2 is
required for proliferation in C2C12 myoblasts.  In addition,
our research indicates JAK2 also has a novel role in skeletal
muscle myogenesis. These results represent the first
characterization of the requirement of JAK2 in skeletal
muscle proliferation, and suggest a novel role, potentially
independent of kinase activity, for JAK2 in skeletal muscle
myogenesis.
Materials and Methods
Stable Cell Lines
To create DN-JAK2, WT-JAK2, and pRK5 stable cell
lines, the following plasmids were used: pRK5JAK2,
pRK5JAK2M, pRK5 and pGKNeo.  pGKNeo contained a
neomyocin cassette, pRK5JAK2 contained wild-type JAK2
cDNA, and pRK5JAK2M contained dominant-negative,
mutant JAK2 cDNA.  C2C12 cells were co-transfected with
Fugene 6, linearized pGKNeo DNA, and linearized
pRK5JAK2 (WT), pRK5JAK2M (DN), or pRK5 DNA.  To
create the TEL-JAK2 (5-12) and pcDNA3 stable cell lines,
the plasmids pcDNA3-TEL-JAK2 (5-12) and pcDNA3 were
used.  Cells were transfected as described for DN-JAK2
stable cells.  After 18 hours of incubation in transfection
media, cells were changed to growth media that contained
G418.  Subclones that expressed the genes of interest were
maintained by continual selection with G418.  Clones were
confirmed by western blot analysis of JAK2 over-
expression.
Cell Proliferation
Myoblasts were incubated with 10 µM BrdU and dCTP
for the final 12 hours of the proliferation assay time course.
Cells were fixed and incubated with blocking buffer (PBS-T
+ 1.0% bovine serum albumin) containing anti-mouse BrdU
antibody.  After incubation, plates were washed with PBS-
T.  Blocking buffer with secondary anti-mouse IgG, FITC-
conjugated antibodies was added to the plates.  Cells were
washed and incubated with Hoeschst 33258.   Total and
proliferated nuclei were quantified by visualization of
HO33258 and FITC positive nuclei, respectively.  To
determine the percentage of proliferated cells, FITC-
positive nuclei were divided by the total number of nuclei.
Terminal Differentiation
Cells were photographed throughout experiments.  At
the time of collection, cells were washed with PBS, and 0.5
M glycylglycine buffer, pH 6.75, was added to the plates.
After collection, cells were sonicated and centrifuged to
pellet cell debris.  The supernatant was collected and
creatine kinase (CK) activity was determined as described
by the manufacturer’s protocol (Sigma).  Total protein was
quantified with the Bradford protein assay.  Creatine kinase
units were reported corrected for total protein in nanograms.
Results and Discussion
Inhibition of JAK2 blocks myoblast proliferation in C2C12
cells
To determine if JAK2 signaling was required for
C2C12 myoblast proliferation, myoblasts were incubated
with 0.2, 2, or 20 _M AG490 (Figure 1A).  C2C12 cells
incubated with AG490 had a dose-dependent decrease in
myoblast proliferation (p ≤ 0.0001; Figure 1).  Cells treated
with 20 µM of AG490 had almost no BrdU incorporation
(2.3%) vs. control cells (66%).  These results indicate that
JAK2 activity may be required for C2C12 myoblast
proliferation.  As a second way to examine the effect of
JAK2 on proliferation, the rate of proliferation was
quantified in stable C2C12 lines that expressed dominant-
negative (DN) and wild-type (WT) JAK2.  Cells that
expressed dominant-negative JAK2 had decreased levels of
proliferation as compared to cells that expressed wild-type
JAK2 or control cells (p ≤ 0.0001).  These results indicate
that expression of a dominant-negative JAK2 attenuates
proliferation in C2C12 myoblasts.
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Figure 1.  AG490 inhibits myoblast proliferation.
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Constitutively active JAK2 increases proliferation in C2C12
myoblasts
To determine if JAK2 could increase proliferation,
constitutively active JAK2 was expressed in C2C12 cells.
The constitutively active JAK2 construct consisted of a
fusion protein between the ets transcription factor TEL and
JAK2.  TEL-JAK2 myoblasts had a significantly higher
percentage of myoblasts that proliferated than control cells
(p ≤ 0.01).  These results demonstrate that expression of a
constitutively active form of JAK2 was sufficient to increase
proliferation in C2C12 cells.
Inhibition of JAK2 with AG490 blocks terminal
differentiation in C2C12 cells
To determine if JAK2 signaling was required for
terminal differentiation in C2C12 myoblasts, cells were
cultured for 72 hours in differentiation media (DM) that
contained 0.2, 2 or 20 _M AG490.  Creatine kinase activity,
a marker of terminal differentiation in skeletal muscle, was
significantly inhibited by 2 _M (p ≤ 0.05) and 20 _M (p ≤
0.0001) AG490 (Figure 2).  The results indicate that, like
proliferation, terminal differentiation is inhibited by AG490.
However, only high concentrations of AG490 inhibited
myogenesis, whereas low concentrations were sufficient to
block myoblast proliferation.
Figure 2.  AG490 inhibits terminal differentiation in
myoblasts.
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C2C12 cells stably transfected with DN-JAK2, WT-JAK2
and TEL-JAK2 have enhanced terminal differentiation
To confirm the AG490 results, we quantified the
terminal differentiation of stable C2C12 lines that express
DN-JAK2, WT-JAK2 or control cells.    Interestingly, cells
that over-express JAK2 (DN- and WT-JAK2 C2C12 cells)
had significantly higher levels of CK activity than control
cells (p ≤ 0.05).  Strikingly, DN-JAK2 C2C12 cells had the
greatest increase in CK activity (p ≤ 0.0001; Figure 5A).
This is in contrast to our previous experiments in which
AG490 was used to block JAK2 activity.  In addition, cells
that over-express a constitutively active JAK2 (TEL-JAK2)
had significantly higher levels of CK activity over control
cells (p ≤ 0.001; Figure 5B). These results suggest a role for
JAK2 protein in the promotion of terminal differentiation in
C2C12 cells that is independent of kinase activity.
Acknowledgements
We thank Dr. Cong Zong, with kind permission from Dr.
David E. Levy, for graciously providing pRK5JAK2 and
pRK5JAK2M constructs, Dr. Dwayne Barber for
generously providing pcDNA3-TEL-JAK2 constructs, Dr.
Ted Huiatt for providing antibodies, reagents and valuable
advice, Dr. Janice Buss for excellent advice, and Dr. Curtis
Youngs, Dr. Steven Lonergan, Dr. Elisabeth Huff-
Lonergan, and Dr. Donald Beitz for kindly allowing the use
of critical equipment.  This study was partially supported by
a USDA National Needs fellowship and the ISU
Biotechnology Council.
